Midatech Biogune, an auxiliary company of the Midatech Group, has declared that it has received an Investigational Medicinal Products (IMP) License to produce nanoparticles of clinical quality at its advanced facility in Bilbao, Spain. The company received the IMP License from the Spanish Medicines Agency. The company designs, develops, and produces nanomedicines.
An inspection was conducted at the company’s Spain facility on the 15th and 16th of February 2011 and received the accreditation from the Spanish Medicines Agency. Under the latest European regulations, Midatech became one of the first companies to receive the IMP license in Spain.
The biocompatible nanoparticles, manufactured by Midatech, feature several unique properties to suit therapeutic and diagnostic applications. The nanoparticles dissolve in water and diffuse without restraint in vivo. It is also possible to target particular cells using nanoparticles .Unbound nanoparticles with a diameter of five nm or less can be flushed out quickly by the kidneys thus lowering the probability of non-specific in vivo accumulation of nanoparticles.
When multiple ligands are attached to the surface of nanoparticles, it can be useful in multi-drug delivery or multivalent drug delivery on a single particle.